Cabozantinib and Pembrolizumab in Metastatic Pancreas

NCT05052723 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Cabozantinib
DRUG: Pembrolizumab

Sponsor

Joseph Kim

Collaborators

[object Object]
[object Object]